16 April 2021 12:00 BST --AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals, Inc (Alexion) has achieved an important step toward completion, having cleared US Federal Trade Commission review. This follows the conclusion of the waiting period under the Ha...
competitive, governmental, technological and other factors that may affectAstraZeneca'sandAlexion's operations are discussed in the section entitled "Risk Factors," in each ofAstraZeneca'sAnnual Report on Form 20-F for the year ended31 December 2019...
“ Sickle Cell Disease Pipeline Insight, 2024 “ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sickle Cell Disease Market. Some of the key takeaways from the Sickle Cell Disease Pipeline Report: Companies across the...
technological and other factors that may affect AstraZeneca's and Alexion's operations are discussed in the section entitled "Risk Factors," in each of AstraZeneca's Annual Report on Form 20-F for the year ended 31 December 2019, and Alexion's Annual Report on Form 10-K for the year end...
December 23, 2024 · 207 min read · BioSpace Editorial Staff Drug shortages FDA Confirms Lilly’s GLP-1s Are Not in Shortage, Gives Compounders Grace Period December 19, 2024 · 3 min read · Tristan Manalac Layoffs Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs ...
Alexion continues to innovate with ULTOMIRIS, with the goal of improving the patient experience. We plan to submit regulatory filings in the U.S. and EU in the third quarter of 2021 for an ULTOMIRIS subcutaneous formulation and device comb...